linjc16/ctgov huggingface dataset:
Prone Position for Non-intubated Patients With Acute Respiratory Failure

Study Overview
=================
Brief Summary
-----------------
The study will test the hypothesis that the prone position can be used to reduce the need for intubation and mechanical ventilation in patients with acute respiratory failure.

Official Title
-----------------
Prone Position for Non-intubated Patients With Acute Respiratory Failure

Conditions
-----------------
Respiratory Failure

Intervention / Treatment
-----------------
* Other: Prone position


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: bilateral pulmonary infiltrates or unilateral infiltrates involving more than one lobe on CXR PaO2/FIO2 < 40 kPa RR > 25, or attending intensivist considering likelihood of intubation > 50% Exclusion Criteria: unsuited for the prone position fulfilled inclusion criteria for more than 5 days (120 h) immunosuppression chronic lung disease decision of withdrawal or limitation of therapy pulmonary infiltrates of cardiac origin decreased GCS level PaCO2 > 10 attending intensivist considering the patient unsuited for the prone position BMI > 33

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>Prone position + all conventional treatment. | Other: Prone position<br>* Prone position during spontaneous breathing.<br>|
| No Intervention: Control<br>Conventional treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Need for intubation and mechanical ventilation |  | Duration of hospital stay |
Two Strategies for Methicillin-resistant Staphylococcus Aureus (MRSA) Infection Prevention in Surgical Patients

Study Overview
=================
Brief Summary
-----------------
The study is a two-arm controlled multi-centre trial of two strategies to reduce nosocomial MRSA transmission and infection among surgical patients. Enrolment and primary analyses will be performed at the hospital level. A total of ten adult surgical departments with at least 3 surgical subspecialties each will participate in the study. Sites of the study are located in 9 countries (UK, France, Spain, Germany, Switzerland, Italy, Serbia, Greece and Israel). The primary objective is to determine the effect of an early MRSA detection & decolonization & isolation strategy compared to an enhanced standard control strategy on healthcare-associated MRSA isolation rates among surgical patients at risk of MRSA carriage, who are hospitalized for at least 24 hours.

Official Title
-----------------
An Interventional Study to Evaluate the Impact of Two Innovative Strategies in Preventing Nosocomial MRSA Infection in Surgical Patients

Conditions
-----------------
MRSA Infection

Intervention / Treatment
-----------------
* Other: Rapid molecular MRSA test
* Behavioral: Hand hygiene promotion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Surgical patients with LOS>24h Exclusion Criteria: Surgical patients with LOS<24h
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Rapid detection | Other: Rapid molecular MRSA test<br>* PCR-based rapid screening for MRSA carriage<br>|
| Other: 2<br>Enhanced infection control | Behavioral: Hand hygiene promotion<br>* Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance Standard precautions (e.g. use of gloves for contacts with wounds and body fluids) Isolation precautions according to the hospitals' capacity and strategy Additional basic infection control interventions (if necessary)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nosocomial MRSA isolation rate (expressed as the monthly rate of MRSA in clinical isolates divided by the number of susceptible patients per hundred) |  | Monthly | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nosocomial MRSA infection rate (= number of nosocomial MRSA infections per 100 admissions) |  | Monthly | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Staphylococcus aureus, Resistance, Prevention
CADASIL Registry Study

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine the clinical spectrum and natural progression of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) and related disorders in a prospective multicenter study, to assess the clinical, genetic and epigenetic features of patients with CADASIL , to optimize clinical management.

Official Title
-----------------
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Registry Study

Conditions
-----------------
Cadasil

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sign informed consent. Age>18 Clinical diagnosis of patients with CADASIL,and confirmed by genetic test or skin biopsy Asymptomatic NOTCH3 mutation carriers Relatives of CADASIL patients or carriers Unrelated healthy controls Exclusion Criteria: Unable to cooperate with inspectors Serious systemic illness, such as heart, liver, kidney disease or major mental illness Contraindications for imaging examination

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CADASIL patients<br> | |
| Asymptomatic carriers of CADASIL<br> | |
| Relatives of CADASIL patients and carriers<br> | |
| Unrelated healthy controls<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall outcomes in CADASIL patients | record the occurrence of stroke and use modified Rankin Scale (mRS) to measure the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. | From date of enrollment until the date of death from any cause, assessed up to 20years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The correlation of genotype and phenotype | Genotype is defined by NOTCH3 pathogenic variant position and phenotype is defined by clinical types and characteristics. | From date of enrollment until the date of death from any cause, assessed up to 20years |
Multimodal Assessment of the Neurological Prognosis of Patients With Brain Lesions on ExtraCorporeal Life Support

Study Overview
=================
Brief Summary
-----------------
It seems of the greatest importance to evaluate the neurological prognosis of patients with brain lesions after cardiorespiratory arrest or circulatory failure requiring circulatory assistance. However, to date, there is no clinical or paraclinical diagnostic test to reliably assess the future of these patients. The objective of this study is to highlight the clinical and imaging factors for establishing a neurological prognosis in patients at risk of brain lesions under ExtraCorporeal Life Support (ECLS).

Official Title
-----------------
Multimodal Assessment of the Neurological Prognosis of Patients With Brain Lesions on ExtraCorporeal Life Support

Conditions
-----------------
Brain-injured Patients on Extracorporeal Life Support

Intervention / Treatment
-----------------
* Other: clinical examinations
* Other: neurological assessment when a neurological event occurs
* Other: mortality assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with brain lesions on veno-arterial circulatory support after cardiac arrest or cardiogenic shock who require at least 24 hours of sedation Exclusion Criteria: Extubation expected within the first 24 hours of management Minor patient Pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: clinical examinations|Collection of data from the following tests at H0 (as soon as the ECLS is put in place), H12 (within 12 hours following stabilisation of the dynamic state), H24 and every day until complete neurological recovery: right and left pupillometry (3 times) BIS values right and left NIRS values right and left transcranial Doppler neurological clinical examination|
|Other: neurological assessment when a neurological event occurs|next neurological event: seizures pupillary asymmetry myoclonias brain stem reflex abnormalities osteotendinous reflex abnormalities|
|Other: mortality assessment|to 28 days|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Early mortality assessment |  | 28 days |
A Randomised, Cross-over, Open-labelled Test Catheter Acceptance Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate that the test catheter is no less accepted than the SpeediCath (SC) catheter.

Detailed Description
-----------------
See brief summary

Official Title
-----------------
A Randomised, Cross-over, Open-labelled Study Evaluating the Acceptance of Test Catheters Compared to SpeediCath Catheters

Conditions
-----------------
Spinal Cord Injuries

Intervention / Treatment
-----------------
* Device: test intermittent catheter
* Device: Intermittent catheterization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years of age Has normal/impaired sensation in the urethra Self-catheterises at least 4 times per day Has used clean self-intermittent catheterisation for at least 14 days Is able to open and prepare the catheters for catheterisation Has signed the informed consent before any study related-activities. Exclusion Criteria: Has a symptomatic urinary tract infection as assessed by the investigator Is mentally unstable as assessed by the investigator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: test intermittent catheter<br>CH 12 hydrophilic coated catheter | Device: test intermittent catheter<br>* CH 12 hydrophilic coated catheter<br>* Other names: Test catheter;|
| Experimental: intermittent catheter<br>CH 12 hydrophilic coated catheter | Device: Intermittent catheterization<br>* CH 12 hydrophilic catheter<br>* Other names: SpeediCath;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Discomfort Measured on a VAS Scale 0 Being no Discomfort, 10 Being Worst Imaginable Discomfort. | Participants were to test the catheter by self-catheterising a minimum of 4 catheters each day for 14 days. At the end of each study period participants were asked to indicate how they would rate the discomfort experienced during the catheterisation procedures. Discomfort was measured by the participants own rating of discomfort on a VAS scale from 0 (no discomfort) to 10 (worst imaginable discomfort) | 14 days |
Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer

Study Overview
=================
Brief Summary
-----------------
This study will evaluate feasibility and acceptability of providing the Dignity Therapy/Life Plan intervention to pancreatic or advanced lung cancer patients presenting for treatment in the outpatient medical oncology setting. Investigators hypothesize that providing dignity therapy to this population will be feasible.

Official Title
-----------------
Phase I/IIA: Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer

Conditions
-----------------
Pancreatic Cancer, Non-Small-Cell Lung Cancer

Intervention / Treatment
-----------------
* Behavioral: Dignity Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 Undergoing chemotherapy for pancreatic adenocarcinoma or advanced NSCLC (pancreatic arm closed) English-speaking Cognitively intact, per clinician judgment, as documented in electronic medical record (EMR) Exclusion Criteria: Currently receiving hospice or palliative care services Concurrent diagnosis of delirium or dementia, per medical record Diagnosis of major depression disorder, acute anxiety disorder or schizophrenia per medical record Participating in other psychosocial intervention research studies.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dignity Therapy<br> | Behavioral: Dignity Therapy<br>* Dignity Therapy/Life Plan will be provided by an advanced practice nurse or chaplain (APN/Chap), who has undergone training in provision of Dignity Therapy (offered through a 3-day group workshop by Dr. Harvey Chochinov).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in level of distress as measured by distress scores on the Distress Thermometer |  | Baseline & at the end of the dignity therapy intervention (approximately 6 weeks) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pancreatic Cancer, Dignity Therapy, Palliative Care, Advanced Lung Cancer, Non-Small-Cell Lung Cancer
Assessment of the Rosacea Prevalence in the General Population

Study Overview
=================
Brief Summary
-----------------
Multi-centre interventional cross-sectional prevalence study Assessment of the Rosacea Prevalence in the General Population.

Detailed Description
-----------------
Primary objective: Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis

Official Title
-----------------
Assessment of the Prevalence of Rosacea in the General Population

Conditions
-----------------
Rosacea

Intervention / Treatment
-----------------
* Other: Prevalence assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Part I Inclusion Criteria: The following subjects will be included in the study: Subjects aged 18 to 65 years old from the general population Subjects who are willing to complete the questionnaires Part II Inclusion Criteria: The following subjects will be included in Part II of the study: Subjects who screened positive for rosacea during the first part of the study and selected by random method Subjects who gave their informed consent to participate in Part II of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Prevalence assessment|Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of subjects with rosacea diagnosis confirmed | estimation of the percentage of rosacea patients in the general population | general population will be surveyed over an expected average duration of 6 months |
Outcome of Sub-inguinal Varicocelectomy on Normal Semen in Patients Complaining of Orchilagia With Normal Semen

Study Overview
=================
Brief Summary
-----------------
varicoclelectomy is done for subfertiltiy and varicocele induced orchialgia. The effect of varicocelectomy on semen analysis is controversial. Many articles report favorable outcomes and others do not. Most study don't focus on varicocelectomy done for varicocele induced orchialgia,and those studies dont report on postoperative semen. This study will focus on the effect of operation on the semen postoperatively .

Official Title
-----------------
the Effect of Sub-inguinal Varicocelectomy in Patients Complaining of Orchialgia With Normal Semen Analysis

Conditions
-----------------
Varices; Cord

Intervention / Treatment
-----------------
* Procedure: subinguinal varicocelectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary varicocele. Patient's age more than 20 years. Scrotal pain (after exclusion of other causes). Normal semen analysis Exclusion Criteria: Secondary varicocele. Recurrent varicocele.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: subinguinal varicocelectomy|varicocele ligation done at the level of subinguinal region|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Grades of Motility of sperm in semen analysis | semen analysis | 3 months after the operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Count of sperms in semen analysis | semen analysis | 3 months after the operation |
AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
This 48-week study will compare AVANDAMET vs. Metformin monotherapy for blood glucose control in patients with Type 2 Diabetes Mellitus.

Official Title
-----------------
AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-week Randomized, Open-label, Multicenter Study to Compare the Efficacy and Tolerability of AVANDAMET to Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Control on Submaximal Metformin.

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: rosiglitazone/metformin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients between 18 and 75 years of age with Type 2 Diabetes Mellitus and are currently on metformin monotherapy for glycemic control (100mg daily for at least 3 months prior to screening). Patients must have stopped previous treatment with thiazolidinediones or other anti-diabetic agents at least 3 months prior to screening. Women must be post-menopausal, surgically sterile or using acceptable contraceptive measures. Exclusion Criteria: Prior history of hepatocellular reaction to or severe edema associated with the use of thiazolidinediones. Have a known hypersensitivity to thiazolidinediones or biguanides. Currently using insulin or any oral anti-diabetic agent other than metformin. History of metabolic acidosis. History of substance abuse. Have active cancer other than localized squamous or basal cell carcinoma. Chronic disease requiring treatment with corticosteroids. Other criteria will be evaluated at the screening visit.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: rosiglitazone/metformin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in HbA1c at week 48. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in FPG at week 48. Time to glycemic control. Change from baseline in C-peptide and insulin at week 48. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Metformin, AVANDAMET, Type 2 diabetes